Search
SOLACI Congress
HomeCONGRESSInternational Congresses

International Congresses

View Category
Antiplatelet

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these...
Dr. Omar Tupayachi -
Learn More
Left Atrial Apendix Closure

AHA 2025 | CLOSURE-AF: Left Atrial Appendage Occlusion (LAAO) vs. Medical Therapy in Atrial Fibrillation with High Stroke and Bleeding Risk

Atrial fibrillation (AF) is a complex condition in which patients often present with multiple comorbidities, including high...
Dr. Omar Tupayachi -
Learn More
Antiplatelet

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially...
Dr. Omar Tupayachi -
Learn More
Chronic Ischemic cardiopathy

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been...
Dr. Omar Tupayachi -
Learn More
Antiplatelet

AHA 2025 | DAPT-MVD: Extended DAPT vs. Aspirin Monotherapy After PCI in Multivessel Disease

In patients with multivessel coronary artery disease who remain stable 12 months after drug-eluting stent (DES) stenting,...
Dr. Omar Tupayachi -
Learn More
Antiplatelet

AHA 2025 | TUXEDO-2: Post-PCI Antiplatelet Management in Diabetic Patients with Multivessel Disease — Ticagrelor or Prasugrel?

Choosing the optimal P2Y12 inhibitor for diabetic patients with multivessel coronary artery disease undergoing percutaneous coronary intervention...
Dr. Omar Tupayachi -
Learn More
Coronary Disease

AHA 2025 | DECAF: Coffee Consumption vs. Abstinence in Patients with Atrial Fibrillation: Recurrence or Myth?

The link between coffee consumption and arrhythmia has been met with contradicting recommendations. It is widely believed...
Dr. Omar Tupayachi -
Learn More
Infrapatellar

TCT 2025 | LIFE-BTK: Three-Year Results of the Everolimus-Eluting Resorbable Scaffold in Infrapopliteal Lesions in Patients with Critical Limb Ischemia

Patients with chronic limb-threatening ischemia (CLTI) are among the most challenging in endovascular revascularization. While endovascular treatment...
Dr. Omar Tupayachi -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Dr. Omar Tupayachi - 0
Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy